Treg-Directed Therapies Summit on March 25-27, 2025 in Boston, United States

Over the past year, the Treg sector has seen groundbreaking investments and strategic collaborations between leading biotech and pharma companies like Quell and AstraZeneca, and Parvus and AbbVie, creating a surge of innovation and spotlighting Treg cell therapies and modulators as the next frontier in autoimmune and inflammatory disease treatments. Tregs hold the potential to revolutionize care for conditions that have long lacked effective solutions and are the future of precision medicine in autoimmune and inflammatory diseases.

URLs:

Tickets: https://go.evvnt.com/2753136-0?pid=10008

Brochure: https://go.evvnt.com/2753136-3?pid=10008

Time: 8:00 AM - 5:00 PM

Prices:

Drug Developer Pricing - Conference + Treg Biology Focus Day: USD 4197.00,

Drug Developer Pricing - Conference Only: USD 2999.00,

Academic and Start-Up Pricing - Conference + Treg Biology Focus Day: USD 3597.00,

Academic and Start-Up Pricing - Conference Only: USD 2599.00,

Solution and Service Provider Pricing - Conference + Treg Biology Focus Day: USD 5097.00,

Solution and Service Provider Pricing - Conference Only: USD 3699.00

Speakers: Adel Nada, Co-founder and Executive Chairman, Trutina Pharma, Birgit Schultes, Senior Vice President, Cell Therapeutics, Intellia Therapeutics, Charles Sentman, Professor, Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dan Shelly, Chief Business Development Officer, PolTREG, Daniela Cipolletta, Senior Director, Immunology, Seismic Therapeutic, Fabien Depis, Independent Consultant, , Haining Huang, President and Co-Founder, Cytimm Therapeutics, Hong Jiang, Founder and Chief Scientific Officer, Avotres, James Adams, Chief Technical Officer, Tr1x Bio, James Dooley, Principal Research Associate, Liston-Dooley Laboratory, University of Cambridge, Department of Pathology, James Mathew, Professor, Northwestern University, Joseph Leventhal, Scientific Founder, Tract Therapeutics, Julie Di Paolo, Senior Director Immunology, Scientific Innovation Lead, Johnson and Johnson, Khaled Ali, Director, Immunology Research, GlaxoSmithKline Plc, Kristie Grebe, Chief Scientific Officer, Anokion Inc., Lenny Dragone, Chief Medical Officer, Abata Therapeutics, Louis-Marie Charbonnier, Assistant Professor of Pediatrics, Harvard Medical School, Marc Martinez-Llordella, Co-founder and Vice President, Biology, Quell Therapeutics, Miguel Forte, Chief Executive Officer, Kiji Therapeutics, Miguel Marin Rodero, Immunology PhD Candidate, Cristophe Benoist-Diane Mathis Laboratory, Harvard Medical School, Natasha Girgis, Director, Translational Pharmacology, Cue Biopharma, Paul Peloso, Chief Medical Officer, COUR Pharmaceuticals, Payam Zarin, Associate Director, Discovery Research, GentiBio, Pere Santamaria, Chief Scientific Officer, Parvus Therapeutics, Rachel Hourigan, Research Analyst Lead, Beacon, Rafael Correa-Rocha, Chief Scientific Officer, ThyTech, Saul Kivimae, Vice President and Head of Pharmacology, Nektar Therapeutics, Stefanie Koristka, Principal Scientist, Cell Therapy, Intellia Therapeutics, Talal Chatila, Professor of Pediatrics, Harvard Medical School, Tony Ting, Chief Scientific Officer, Kiji Therapeutics, Weston Daniel, Chief Development Officer, EVOQ Therapeutics, Zengli Guo, Associate Director, Cell Therapeutics, AstraZeneca